India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has suspended the Ethics Committee of HCG Bengaluru Institute of Oncology for a period of 24 months following findings of significant regulatory non-compliance related to clinical trials. The action highlights the growing emphasis on patient safety, ethical oversight, and regulatory accountability in clinical research across the country.
Why Did CDSCO Take Action?
According to the suspension order issued by the Central Licensing Authority under the New Drugs and Clinical Trials Rules (NDCTR), 2019, the Ethics Committee was found to have violated several regulatory requirements. The alleged deficiencies included:
- Inadequate reporting of Serious Adverse Events (SAEs)
- Protocol deviations during clinical trials
- Failure to ensure proper management and protection of trial participants
- Non-compliance with ethical and regulatory obligations related to ongoing studies
The suspension order was issued on 12 June 2026 by the Drugs Controller General of India (DCGI).
Impact of the Suspension
The suspension effectively prevents the Ethics Committee from reviewing, approving, or overseeing any new clinical trials or bioavailability-bioequivalence (BA/BE) studies at the institution for the next two years.
However, ongoing clinical trials will continue under strict regulatory monitoring. The Ethics Committee has been directed to:
- Continue monitoring existing clinical trials
- Submit monthly safety reports to the CDSCO Zonal Office, Bengaluru
- Submit Corrective and Preventive Action (CAPA) reports
- Report previously unreported Serious Adverse Events
- Provide compensation details where applicable for affected participants
Background of the Investigation
The regulatory action follows concerns raised regarding alleged ethical and compliance lapses in clinical trials conducted at the Bengaluru-based cancer hospital. Complaints highlighted issues related to patient safety, conflicts of interest, and adherence to clinical trial regulations. These concerns prompted inspections and investigations by regulatory authorities.
Following the inspection process, CDSCO concluded that corrective regulatory action was necessary to ensure compliance with national clinical trial standards.
Role of Ethics Committees in Clinical Trials
Ethics Committees play a critical role in safeguarding the rights, safety, and well-being of clinical trial participants. Under CDSCO regulations, no clinical trial can be approved without review and authorization by a registered Ethics Committee. These committees are responsible for:
- Reviewing clinical trial protocols
- Monitoring participant safety
- Assessing informed consent procedures
- Reviewing adverse event reports
- Ensuring compliance with ethical guidelines and regulatory requirements
Significance for Clinical Research in India
The suspension serves as a reminder that regulatory authorities are strengthening oversight of clinical research activities. Ensuring transparency, timely adverse event reporting, and participant protection remains a top priority for regulators.
Industry experts believe such actions may encourage institutions, investigators, and Ethics Committees across India to reinforce compliance mechanisms and improve monitoring systems for clinical trials.
Conclusion
The CDSCO’s decision to suspend the HCG Bengaluru Ethics Committee for two years underscores the importance of maintaining the highest ethical and regulatory standards in clinical research. While ongoing studies will continue under enhanced supervision, the case highlights the critical role Ethics Committees play in protecting trial participants and ensuring the integrity of clinical trials in India.
Recommended Products
